Protara Therapeutics (TARA) Interest Coverage Ratio (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Interest Coverage Ratio of 2.22 for Q1 2026, up 33.61% year-over-year from 1.66 in Q1 2025, and up 95.85% quarter-over-quarter from 53.44 in Q4 2025.
Protara Therapeutics (TARA) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Interest Coverage Ratio for 14 consecutive years, with 2.22 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 33.61% year-over-year to 2.22; the TTM figure through Mar 2026 stood at 7.92 (up 34.92% YoY), while the FY2025 annual figure was 0.77, down 13.88% from the prior year.
- Interest Coverage Ratio grew to 2.22 in Q1 2026 per TARA's latest filing, from 53.44 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2.22 in Q1 2026 and bottomed at 119.0 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 21.54 across 5 years, with a median of 7.01 in 2022.
- On a YoY basis, Interest Coverage Ratio climbed as much as 97.45% in 2022 and fell as far as 2565.33% in 2022.
- Protara Therapeutics' Interest Coverage Ratio stood at 119.0 in 2022, then soared by 61.18% to 46.2 in 2023, then advanced by 6.68% to 43.11 in 2024, then slipped by 23.97% to 53.44 in 2025, then jumped by 95.85% to 2.22 in 2026.
- Business Quant data shows TARA's Interest Coverage Ratio at 2.22 in Q1 2026, 53.44 in Q4 2025, and 2.92 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | -7.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.81 |
| Mar 31, 2026 | -2.22 |
| Dec 31, 2025 | -53.44 |
| Sep 30, 2025 | -2.92 |
| Jun 30, 2025 | -3.79 |
| Mar 31, 2025 | -3.34 |
| Dec 31, 2024 | -43.11 |
| Sep 30, 2024 | -2.29 |
| Jun 30, 2024 | -7.46 |
| Mar 31, 2024 | -3.22 |
| Dec 31, 2023 | -46.20 |
| Sep 30, 2023 | -7.67 |
| Jun 30, 2023 | -8.50 |
| Mar 31, 2023 | -29.31 |
| Dec 31, 2022 | -119.00 |
| Sep 30, 2022 | -5.53 |
| Jun 30, 2022 | -6.56 |
| Dec 31, 2021 | -4.46 |
| Sep 30, 2021 | -216.60 |
| Jun 30, 2021 | -220.55 |